Zhimeng Biopharma Overview
- Year Founded
-
2017
- Status
-
Private
- Latest Deal Type
-
Series B
- Latest Deal Amount
-
$54.6M
- Investors
-
16
Zhimeng Biopharma General Information
Description
Developer of pharmaceuticals designed to target all stages of the hepatitis B virus. The company has nuclecapsid inhibitor, RNA destabilizer and immunomodulator projects in the pipeline, enabling healthcare professionals to prescribe better treatments to patients.
Contact Information
Website
www.core-biopharma.comCorporate Office
- Suite A-302
- No. 1976 Gaoke Middle Road, China (Shanghai) Pilot Free Trade Zone
- Shanghai, 201210
- China
Corporate Office
- Suite A-302
- No. 1976 Gaoke Middle Road, China (Shanghai) Pilot Free Trade Zone
- Shanghai, 201210
- China
Zhimeng Biopharma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Early Stage VC (Series B) | 08-Nov-2021 | $54.6M | Completed | Clinical Trials - Phase 1 | ||
| 3. Early Stage VC (Series A) | 06-Nov-2020 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC | 11-Nov-2019 | $14.2M | $14.2M | Completed | Clinical Trials - Phase 1 | |
| 1. Early Stage VC | 05-Feb-2018 | Completed | Startup |
Zhimeng Biopharma Patents
Zhimeng Biopharma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2023210960-A1 | Amide compound as potassium channel regulator, and preparation therefor and use thereof | Pending | 25-Jan-2022 | ||
| AU-2023211370-A1 | Aromatic ring-fused heterocyclic ring compound as potassium channel regulator, and preparation therefor and use thereof | Pending | 25-Jan-2022 | ||
| EP-4471013-A1 | Aromatic ring-fused heterocyclic ring compound as potassium channel regulator, and preparation therefor and use thereof | Pending | 25-Jan-2022 | ||
| EP-4471022-A1 | Amide compound as potassium channel regulator, and preparation therefor and use thereof | Pending | 25-Jan-2022 | ||
| JP-2025504539-A | Aromatic fused heterocyclic compounds as potassium channel modulators and their preparation and use | Pending | 25-Jan-2022 |
Zhimeng Biopharma Investors (16)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Advantech Capital Partners | Venture Capital | Minority | ||
| Co-Stone Capital | PE/Buyout | Minority | ||
| Dawu Venture Capital | Venture Capital | Minority | ||
| DYEE Capital | Venture Capital | Minority | ||
| Fellow Partners | Venture Capital | Minority |
Zhimeng Biopharma FAQs
-
When was Zhimeng Biopharma founded?
Zhimeng Biopharma was founded in 2017.
-
Where is Zhimeng Biopharma headquartered?
Zhimeng Biopharma is headquartered in Shanghai, China.
-
What industry is Zhimeng Biopharma in?
Zhimeng Biopharma’s primary industry is Drug Discovery.
-
Is Zhimeng Biopharma a private or public company?
Zhimeng Biopharma is a Private company.
-
What is the current valuation of Zhimeng Biopharma?
The current valuation of Zhimeng Biopharma is .
-
What is Zhimeng Biopharma’s current revenue?
The current revenue for Zhimeng Biopharma is .
-
How much funding has Zhimeng Biopharma raised over time?
Zhimeng Biopharma has raised $103M.
-
Who are Zhimeng Biopharma’s investors?
Advantech Capital Partners, Co-Stone Capital, Dawu Venture Capital, DYEE Capital, and Fellow Partners are 5 of 16 investors who have invested in Zhimeng Biopharma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read blog » -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process »
